Treating Minority Patients with Multiple Sclerosis: Development of the CHIMES Trial
Black/African American (Black) and Hispanic/Latino (Hispanic) patients with multiple sclerosis (MS) have greater disease severity, faster disease progression and greater eventual disability than White patients. Despite differences in MS clinical characteristics, Black and Hispanic patients are vastly underrepresented in clinical trials, owing to poor access to care as well as cultural, economic and other institutional enrollment barriers. The objective of the CHIMES trial is to investigate the efficacy and safety of ocrelizumab in Black and Hispanic patients with relapsing MS who meet the US prescribing information criteria in an open-label, single-arm, Phase IV clinical study.